A recently published study shows that Amgen’s ABP 501 (Amjevita), referenced on Humira, shows that the product has similar efficacy, safety, and immunogenicity to its reference in patients with moderate to severe rheumatoid arthritis.
A recently published study shows that Amgen’s ABP 501 (Amjevita), the first adalimumab biosimilar referenced on Humira to be approved by the FDA for the treatment of multiple inflammatory diseases, shows that the product has similar clinical efficacy, safety, and immunogenicity to its reference in patients with moderate to severe rheumatoid arthritis (RA).
Previous phase 1 clinical studies of ABP 501 have demonstrated its pharmacokinetic (PK) equivalence to adalimumab as well as its similarity in clinical efficacy, safety, and immunogenicity compared with reference adalimumab. Two phase 3 studies were undertaken comparing ABP 501 with reference adalimumab, 1 in patients with moderate to severe plaque psoriasis, and 1 in patients with moderate to severe RA. The latter study, by Stanley Cohen, MD, and colleagues, was published online in the Annals of Rheumatologic Disease. The authors report that the phase 3 study, funded by Amgen, demonstrates that ABP 501 is similar to reference adalimumab in clinical efficacy, safety, and immunogenicity in patients with moderate to severe RA.
The randomized, double-blind, active comparator—controlled, 26-week equivalence study enrolled adalimumab-naïve patients, with moderate to severe RA despite methotrexate treatment, who were randomized 1:1 to receive ABP 501 or reference adalimumab. Patients received 40  mg of the biosimilar or reference adalimumab subcutaneously on day 1, and then every 2 weeks until week 22.
The primary endpoint was risk ratio (RR) of the American College of Rheumatology’s (ACR) ACR20 measurement of symptoms (20% improvement in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity, and acute phase reactant) between groups at week 24.
Secondary endpoints included another measure of RA disease activity, the Disease Activity Score 28-joint count-C reactive protein (DAS28-CRP). Safety was assessed by adverse events (AEs) and laboratory evaluations. Immunogenicity was assessed by monitoring antidrug antibodies (ADAs).
Of the 526 randomized patients—264 in the ABP 501 arm and 262 in the adalimumab arm—494 completed the study. At week 24, the ACR20 response was 74.6% for the ABP 501 group and 72.4% for the adalimumab group. The RR of ACR20 between groups was 1.039, confirming the primary hypothesis that the 2 treatments were equivalent.
Changes from baseline on all measurements were similar. There were no clinically meaningful differences in AEs and laboratory abnormalities, and 38.3% (ABP 501) and 38.2% (reference adalimumab) of patients tested positive for binding ADAs. The researchers concluded that ABP 501 and reference adalimumab have similar safety profiles. “No new safety signals were detected in this study compared with other adalimumab clinical trials in patients with RA,” they noted. “Hypersensitivity reactions were reported infrequently and occurred at a generally similar frequency in both treatment groups.”
In conclusion, the researchers say that data from this study show that the clinical efficacy, safety, and immunogenicity of ABP 501 are similar to that of reference adalimumab in patients with moderate to severe RA. Analytical, biofunctional, and PK properties of ABP 501 have previously been shown to be highly similar to those of reference adalimumab. Thus, taken together, these data contribute to the totality-of-evidence—based requirements to demonstrate that ABP 501 is similar to reference adalimumab. The FDA’s approval of ABP 501 (Amjevita) adalimumab biosimilar has provided a valuable new therapeutic option for the treatment of moderate to severe RA.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.